C
Charles M. Perou
Researcher at University of North Carolina at Chapel Hill
Publications - 645
Citations - 235604
Charles M. Perou is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 156, co-authored 573 publications receiving 202951 citations. Previous affiliations of Charles M. Perou include North Carolina Central University & University of Chicago.
Papers
More filters
Journal ArticleDOI
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Bryan T. Hennessy,Ana M. Gonzalez-Angulo,Katherine Stemke-Hale,Michael Z. Gilcrease,Savitri Krishnamurthy,Ju Seog Lee,Jane Fridlyand,Aysegul A. Sahin,Roshan Agarwal,Corwin Joy,Wenbin Liu,David N. Stivers,Keith A. Baggerly,Mark S. Carey,Ana Lluch,Carlos Monteagudo,Xiaping He,Victor J. Weigman,Cheng Fan,Juan P. Palazzo,Gabriel N. Hortobagyi,Laura K. Nolden,Nicholas J. Wang,Vicente Valero,Joe W. Gray,Charles M. Perou,Gordon B. Mills +26 more
TL;DR: Metaplastic breast cancers (MBCs) are aggressive, chemoresistant tumors characterized by lineage plasticity as discussed by the authors, and they have unique DNA copy number aberrations compared with common breast cancers.
Journal ArticleDOI
Epidemiology of basal-like breast cancer
Robert C. Millikan,Beth Newman,Chiu Kit Tse,Patricia G. Moorman,Kathleen Conway,Lisa V. Smith,Miriam H. Labbok,Joseph Geradts,Jeannette T. Bensen,Susan A. Jackson,Sarah J. Nyante,Chad A. Livasy,Lisa A. Carey,H. Shelton Earp,Charles M. Perou +14 more
TL;DR: In the Carolina Breast Cancer Study, a population-based, case-control study of African-American and white women, the authors found that up to 68% of basal-like breast cancer could be prevented by promoting breastfeeding and reducing abdominal adiposity as mentioned in this paper.
Journal ArticleDOI
A custom microarray platform for analysis of microRNA gene expression
TL;DR: Dual-channel microarrays are designed that monitor expression levels of 124 mammalian microRNAs and expression profiles of staged embryos demonstrate temporal regulation of a large class of micro RNAs, including members of the let-7 family.
Journal ArticleDOI
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
William M. Sikov,Donald A. Berry,Charles M. Perou,Baljit Singh,Constance Cirrincione,Sara M. Tolaney,Charles S. Kuzma,Timothy J. Pluard,George Somlo,Elisa Port,Mehra Golshan,Jennifer R. Bellon,Deborah Collyar,Olwen Hahn,Lisa A. Carey,Clifford A. Hudis,Eric P. Winer +16 more
TL;DR: In stage II to III TNBC, addition of either carboplatin or bevacizumab to NACT increased pCR rates, but whether this will improve relapse-free or overall survival is unknown.
Journal ArticleDOI
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer
Torsten O. Nielsen,Joel S. Parker,Samuel Leung,K. David Voduc,Mark T. W. Ebbert,Tammi L. Vickery,Sherri R. Davies,Jacqueline E. Snider,Inge J. Stijleman,Jerry S. Reed,Maggie C.U. Cheang,Maggie C.U. Cheang,Elaine R. Mardis,Charles M. Perou,Philip S. Bernard,Matthew J. Ellis +15 more
TL;DR: The PAM50 gene expression test for intrinsic biological subtype can be applied to large series of formalin-fixed, paraffin-embedded breast cancers, and gives more prognostic information than clinical factors and IHC using standard cut points.